Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre Study to Evaluate the Long-term Safety and Tolerability of REN001 in Subjects With Primary Mitochondrial Myopathy (PMM)

NCT05267574 is registered in ClinicalTrials.gov with Reneo Pharma Ltd as lead sponsor.

NCT NCT05267574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre Study to Evaluate the Long-term Safety and Tolerability of REN001 in Subjects With Primary Mitochondrial Myopathy (PMM)
Lead sponsor
Reneo Pharma Ltd
Phase
Phase 2/3
Overall status
Terminated
Start date
February 1, 2022
Completion date
January 31, 2024
Enrollment
155 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

primary mitochondrial myopathy